Back

Monovalent XBB.1.5 mRNA Vaccine Recalls a More Durable and Coordinated Antibody Response to SARS-CoV-2 Spike than the Bivalent WT/BA.5 mRNA Vaccine

Barouch, S. E.; Levine, K. S.; Blanc, R.; Wang, Q.; Tong, X.; McNamara, R. P.

2024-09-13 immunology
10.1101/2024.09.12.612662 bioRxiv
Show abstract

In the fall of 2023, the monovalent XBB.1.5 mRNA vaccine for COVID-19 became available. However, the comparative magnitude, durability, and functionality of antibody responses induced by the XBB.1.5 vaccine compared with the 2022-2023 bivalent wildtype (WT) + Omicron BA.5 vaccine remains to be fully determined. In this study, we compared antibody profiles generated by these two vaccines in healthcare workers. We show that the monovalent XBB.1.5 vaccine induced higher magnitude binding, neutralizing, and Fc-gamma receptor (Fc{gamma}R) binding antibodies to the XBB.1.5 spike compared with the bivalent vaccine against the WT and BA.5 spikes, both at both peak immunogenicity and at 6 months post-vaccination. Moreover, antibody interaction architectures and correlations remained more robust at 6 months post-vaccination with the XBB.1.5 vaccine, whereas these correlations were largely lost at 6 months with the bivalent vaccine. Our results suggest that the XBB.1.5 vaccine led to a more durable and functionally coordinated antibody response compared to the bivalent vaccine.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
npj Vaccines
○ 67 papers in training set
Top 0.1%
30.5%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 17%
10.4%
Similar papers in this journal
3
Frontiers in Immunology
○ 638 papers in training set
Top 2%
7.1%
Similar papers in this journal
4
mBio
● 833 papers in training set
Top 3%
5.4%
Similar papers in this journal
50% of probability mass above
5
eLife
● 5828 papers in training set
Top 33%
3.5%
Similar papers in this journal
6
Cell Reports
○ 1498 papers in training set
Top 11%
3.5%
7
eBioMedicine
○ 183 papers in training set
Top 1%
3.2%
8
Science Immunology
● 88 papers in training set
Top 0.9%
3.2%
9
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.6%
10
iScience
○ 1154 papers in training set
Top 12%
2.3%
11
Cell
○ 431 papers in training set
Top 5%
2.1%
12
Med
○ 39 papers in training set
Top 0.2%
1.7%
13
Vaccine
○ 203 papers in training set
Top 1%
1.5%
14
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 32%
1.3%
15
Microbiology Spectrum
● 469 papers in training set
Top 9%
1.1%
16
Nature Medicine
○ 125 papers in training set
Top 3%
1.1%
17
Scientific Reports
○ 3612 papers in training set
Top 65%
1.1%
18
Immunity
○ 67 papers in training set
Top 1%
1.1%
19
Science Advances
● 1243 papers in training set
Top 26%
1.1%
20
Nature Immunology
○ 79 papers in training set
Top 2%
0.8%
21
PLOS Pathogens
● 820 papers in training set
Top 9%
0.8%
22
PNAS Nexus
◐ 159 papers in training set
Top 4%
0.8%
23
Biomaterials
○ 84 papers in training set
Top 2%
0.6%
24
Science
● 477 papers in training set
Top 10%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.